HSP90AB1 and gastrointestinal stromal tumor: Furthermore, a new orally available HSP90 inhibitor, TAS-116 (Pimitespib), was recently approved to treat gastrointestinal stromal tumors that have progressed after chemotherapy in Japan [38].